Abstract 1527P
Background
We previously reported that the superiority of modified FOLFIRINOX (mFOLFIRINOX) and S-IROX (S-1, irinotecan, and oxaliplatin) compared with Gemcitabine (G) plus nab-paclitaxel (nP) (GnP) were not demonstrated as first-line treatment for metastatic pancreatic cancer (MPC). We report the final follow-up updated data.
Methods
This randomized, open-label, phase 2/3 trial was done in 45 Japanese centers. Eligible patients (pts) were aged 20–75 years and had an ECOG PS of 0–1 with pathologically confirmed metastatic or recurrent pancreatic cancer. Pts were randomly allocated (1:1:1) to receive GnP (G 1,000 mg/m2 and nP 125 mg/m2 on days 1, 8, 15, every 4 weeks), mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2,and l-leucovorin 200 mg/m2 on day 1, and 5-FU 2,400 mg/m2 on days 1–3, every 2 weeks), or S-IROX (oxaliplatin 85 mg/m2 and irinotecan 150 mg/m2 on day 1, and S-1 80 mg/m2/day on days 1–7, every 2 weeks). The primary endpoint was overall survival (OS).
Results
From Apr 2019 to Mar 2023, 527 pts were included and analyzed for the final analysis. The median OS was 15.3 mo in the GnP arm, 12.5 mo in the mFOLFIRINOX arm (HR 1.27, 95% CI 1.01–1.61), and 13.2 mo in the S-IROX arm (HR 1.23, 95% CI 0.98–1.56). The median progression-free survival was 6.5 mo in the GnP arm, 5.9 mo in the mFOLFIRINOX arm (HR 1.06, 95% CI 0.86–1.32), and 6.0 mo in the S-IROX arm (HR 0.96, 95% CI 0.77–1.20). Subsequent anti-cancer therapy was administered in 85.8% of GnP arm, 86.9% of mFOLFIRINOX arm, and 87.5% of S-IROX arm. Nal-IRI-based regimens were administered as the 2nd-line setting in 22.2% of the GnP arm, 1.1% of the mFOLFIRINOX arm, and 0.6% of the S-IROX arm. In the BRCA mutated pts, OS was longer than that in wild type pts in all 3 arms (GnP 25.9 mo, mFOLFIRINOX 18.4 mo, S-IROX 33.2 mo). Grade 3 or higher anorexia was more frequent in the mFOLFIRINOX (22.8%) and S-IROX (27.6%) arm than in the GnP arm (5.2%).
Conclusions
In the final analysis as well as in the interim analysis, GnP is recommended as the first-line treatment for pts with MPC compared to mFOLFIRINOX or S-IROX.
Clinical trial identification
jRCTs031190009.
Editorial acknowledgement
Legal entity responsible for the study
Japan Clinical Oncology Group (JCOG), Hepatobiliary and Pancreatic Oncology Group (HBPOG).
Funding
Japan Agency for Medical Research and Development; National Cancer Center Research and Development.
Disclosure
S. Kobayashi: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical, Bayer Yakuhin, Eisai Pharmaceutical, Yakult Honsha, Servier Japan, Chugai Pharmaceutical, Eli Lilly Japan, Takeda Pharmaceutical, Otsuka Pharmaceutical, AstraZeneca, Ono Pharmaceutical, Merck Sharp & Dohme, Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Zymeworks. A. Ohba: Financial Interests, Personal, Invited Speaker: Yakult, Ono, Servier, Taiho, Eisai; Financial Interests, Personal, Advisory Board: Zymeworks; Financial Interests, Institutional, Local PI: Ono, Chugai, Novartis. M. Ozaka: Financial Interests, Personal, Invited Speaker: Taiho, Yakult, MSD, Incyte, Ono, Bayer, Servier. J. Mizusawa: Financial Interests, Personal, Other, Honoraria: Chugai Pharmaceutical, Taiho Pharmaceutical; Other, My spouse receives salary: Pfizer. T. Okusaka: Financial Interests, Personal, Advisory Board: Eisai, Nihon Servier, AstraZeneca, Fujifilm Toyama Chemical; Financial Interests, Personal, Invited Speaker: AstraZeneca, Eisai, Chugai Pharma, Nihon Servier, Incyte, Novartis, Daiichi Sankyo, Taiho, Yakult, Myriad Genetics, Kyowa Kirin, Ono; Financial Interests, Institutional, Local PI: AstraZeneca, Eisai, Bristol Myers Squibb, Incyte, Syneos Health, Chiome Bioscience, Sysmex. M. Ikeda: Financial Interests, Personal, Advisory Board: AstraZeneca, Chugai, Eisai, Nihon Servier, Novartis, Bristol Myers Squibb, MSD, Boehringer Ingelheim, Astellas Pharma, GSK; Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai, Eli Lilly Japan, Eisai, Nihon Servier, Novartis, Taiho, Yakult, Teijin Pharma, AbbVie, Fujifilm Toyama Chemical, Incyte Biosciences Japan, Takeda, Ono, MSD, Taisho Pharmaceutical, Nippon Kayaku, Guardant Health Japan, Nobelpharma; Financial Interests, Institutional, Coordinating PI: Bayer, Bristol Myers Squibb, Eisai, AstraZeneca, Eli Lilly Japan, Chugai Pharmaceutical, MSD, Ono, Novartis, J-Pharma, Chiome Bioscience, Nihon Servier, Delta-Fly Pharma, Syneos Health, Merus. N.V., Merck Biopharma, Boehringer Ingelheim, Invitae, Nobelpharma; Financial Interests, Personal, Steering Committee Member: Chugai, Nihon Servier, Takeda, Novartis, Eisai, Rakuten Medical. N. Sasahira: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical, Eisai, Chugai Pharmaceutical, Takeda Pharmaceutical, AstraZeneca; Financial Interests, Institutional, Funding: Taiho Pharmaceutical, Chugai Pharmaceutical, Daiichi Sankyo, Shionogi, Teijin Pharma. K. Ikezawa: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical, Yakult Honsha, MSD, Myriad Genetics, Asahi Kasei Pharma, Incyte Biosciences Japan, Nihon Servier, Chugai Pharmaceutical, AstraZeneca. N. Okano: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical, Eli Lilly Japan, Eisai, Bayer Yakuhin, Chugai Pharma, Ono Pharmaceutical, Daiichi Sankyo, AstraZeneca, MSD, Incyte, Nihon Servier; Financial Interests, Personal, Funding: J-Pharma. N. Mizuno: Financial Interests, Personal, Invited Speaker: Yakult Honsha, AstraZeneca, Novartis, Fujifilm Toyama Chemical, Taiho Pharmaceutical, Miyarisan Pharmaceutical; Financial Interests, Personal, Advisory Board: AstraZeneca, Boehringer Ingelheim; Financial Interests, Institutional, Local PI: MSD, Incyte, Ono Pharmaceutical, Seagen, Boehringer Ingelheim, Pfizer, AstraZeneca, Servier; Financial Interests, Institutional, Coordinating PI: Novartis. H. Katayama: Financial Interests, Personal, Invited Speaker: Fujifilm cooperation. J. Furuse: Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical, Bayer, Eisai, Eli Lilly Japan, MSD, Yakult Honsha, Chugai Pharma, Novartis Pharma, AstraZeneca, Pfizer, Takeda, Taiho Pharmaceutical, Sanofi, Mylan EPD, EA Pharma, Kyowa Hakko Kirin, Daiichi Sankyo, Teijin Pharma, Servier Japan, Incyte; Financial Interests, Personal, Advisory Board: Fuji film, Mundi Pharma, Onco Therapy Science, Merck Bio, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Chugai Pharma, Astellas, AstraZeneca, Takara Bio, Delta-Fly-Pharma, Incyte Japan; Financial Interests, Institutional, Research Grant: Ono Pharmaceutical, MSD, Merck Bio, J-Pharma, Taiho Pharmaceutical, Takeda, Chugai Pharma, AstraZeneca, Yakult Honsha, Eisai, Daiichi Sankyo, Mochida, Sanofi, Sumitomo Dainippon Bayer, Astellas, Incyte Japan; Financial Interests, Personal, Steering Committee Member: Merck Bio, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Astellas, AstraZeneca, Incyte Japan. M. Ueno: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical, Incyte, MSD, Nihon Servier, Ono Pharmaceutical, Taiho Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical, J-Pharma, Eisai, Yakult Honsha; Financial Interests, Personal, Advisory Board: Nippon Boehringer Ingelheim, Novartis; Financial Interests, Institutional, Local PI: Astellas Pharma, AstraZeneca, Chugai Pharmaceutical, DFP, Daiichi Sankyo, Eisai, Incyte, MSD, Merck Biopharma, Ono Pharmaceutical, Taiho Pharmaceutical, Novartis, J-Pharma, Novocure, Chiome Bioscience. All other authors have declared no conflicts of interest.
Resources from the same session
1445P - Novel DNA methylation markers for early detection of cardia gastric adenocarcinoma and esophageal squamous cell carcinoma
Presenter: Zhiyuan Fan
Session: Poster session 18
Resources:
Abstract
1447P - Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study
Presenter: David Tougeron
Session: Poster session 18
1448P - IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts
Presenter: Christelle de la Fouchardiere
Session: Poster session 18
1449P - Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305
Presenter: Markus Moehler
Session: Poster session 18
1450P - Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial
Presenter: Georg Martin Haag
Session: Poster session 18
1453P - A phase Ib study of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC)
Presenter: Nan Bi
Session: Poster session 18
1454P - An open label phase II study of lenvatinib with pembrolizumab and FLOT in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001)
Presenter: Akihito Kawazoe
Session: Poster session 18